BCL2 and acute myeloid leukemia: I-BET762 (GSK525762) and I-BET-151 (GSK1210151A) (100-300 nM) evoked an antiproliferative effect associated with suppression of BCL2 and CDK6 genes in AML cells including drug resistant counterparts [48,56].